

## **THE EXERCISE PRICE FOR THE WARRANTS OF SERIES TO5 IN OPTICEPT HAS BEEN DETERMINED TO SEK 5.64 AND THE SUBSCRIPTION PERIOD COMMENCES ON 19 MAY 2023**

OptiCept Technologies AB (publ) ("OptiCept" or the "Company") completed a rights issue of units during the fourth quarter of 2022. One (1) unit consisted of seven (7) newly issued shares, one (1) warrant of series TO5 and one (1) warrant of series TO6. Each warrant gives the owner the right to subscribe for one (1) new share in the Company. The exercise price for the warrants of series TO5 is to be determined to 70 percent of the volume-weighted average price in the Company's share on Nasdaq First North Growth Market during the measurement period, from 3 May 2023 up to and including 16 May 2023, however not lower than the quota value and not higher than SEK 19.25 per share. During the measurement period, the volume-weighted average price in the Company's share was approximately SEK 8.06, therefore, the exercise price for the warrants of series TO5 is SEK 5.64. The subscription period for warrants of series TO5 runs from 19 May 2023 up to and including 1 June 2023.

If all the warrants of series TO5 are exercised, the Company will receive approximately SEK 7.8 million before issuing costs. For the warrants to not expire without value, it is required that the holder actively subscribes for new shares no later than 1 June 2023 or sell the warrants no later than 30 May 2023. Please observe that certain nominees might close their application earlier than 1 June 2023.

Complete terms and conditions for the warrants and the prospectus, approved by the Swedish Financial Supervisory Authority and published by the Company on 30 November 2022, is available at the Company's webpage, [www.investor.opticept.se/foretradesemission2022](http://www.investor.opticept.se/foretradesemission2022). The prospectus is also available on the Swedish Financial Supervisory Authority's webpage, [www.fi.se](http://www.fi.se).

### **Summarized terms for the warrants of series TO5:**

Subscription period: 19 May 2023 – 1 June 2023.

Last day of trading warrants of series TO5: 30 May 2023.

Issue volume: 1,380,406 warrants of series TO5, which entitles to subscription of 1,380,406 shares. If all warrants are exercised, the Company will receive approximately SEK 7.8 million before issuing costs.

Exercise price: SEK 5.64 per share.

Dilution: Upon full exercise of the warrants of series TO5, the number of shares increase by 1,380,406 shares, from 29,567,582 to 30,947,988 and the share capital increase by SEK 124,236.52, from SEK 2,661,082.38 to SEK 2,785,318.92. In the event that all warrants of series TO5 are exercised, the dilution amounts to approximately 4.46 percent of the number of shares and votes in the Company.

Please note that warrants that are not exercised no later than 1 June 2023, or not sold no later than 30 May 2023, will expire without value. For warrants not to lose their value, the holder must actively subscribe for new shares or sell the warrants.

**How warrants are exercised**

Nominee-registered warrants (Custody account):

Subscription and payment by exercise of warrants shall be made in accordance with instructions from each nominee. Please contact your nominee for additional information.

Direct-registered warrants (Securities account):

No accounts for issuing nor any instructions regarding payments will be sent out. Subscriptions will be made through simultaneous payment in accordance with the instructions on the application form.

The application form including instructions for payment will be available at the Company's webpage, [www.investor.opticept.se/foretradesemission2022](http://www.investor.opticept.se/foretradesemission2022), and on Aktieinvest FK AB:s webpage, [www.aktieinvest.se](http://www.aktieinvest.se).

**Outcome**

The outcome of the exercise of warrants will be published via a press release on or around 2 June 2023. Shares that have been subscribed and paid for will be registered on the subscriber's securities depository as interim shares (IA) until registration of the issue has been completed with the Swedish Companies Registration Office, whereupon the interim shares automatically will be converted into shares in OptiCept.

**Advisers**

Pareto Securities AB acts as Sole Manager and Bookrunner, and Moll Wendén Advokatbyrå AB is legal adviser to the Company in connection with the exercise of warrants.

**Contacts**

---

For further information, please contact:

Thomas Lundqvist, CEO  
+46 73 268 05 70  
[Thomas.Lundqvist@opticept.se](mailto:Thomas.Lundqvist@opticept.se)

## About Us

---

OptiCept Technologies AB (publ) provides the food and plant industry with technological solutions that contribute to a more sustainable world and enable climate-smart economic growth. OptiCept optimizes biological processes - Increased extraction from raw material, extended shelf life, reduced waste, and improved quality (taste, aroma, color, nutritional content) of the final product.

The positive effects of technology increase efficiency for our customers, better products for the consumers, and minimal impact on our environment. Through patented technology in PEF (pulsed electric field) and VI (Vacuum Infusion), the technology opens up new business opportunities for the food and plant industry worldwide. OptiCept's vision is to contribute to a sustainable world by offering efficient green cutting-edge technology that is easy to use in the areas of FoodTech and PlantTech.

The company is located in Lund and the share is traded on the Nasdaq First North Growth Market. Erik Penser Bank is a Certified Adviser and is available at 08-463 80 00 or [certifiedadviser@penser.se](mailto:certifiedadviser@penser.se).

For further information visit:

[OptiCept Technologies Official Website](https://www.opticept.se)

## Attachments

---

**The exercise price for the warrants of series TO5 in OptiCept has been determined to SEK 5.64 and the subscription period commences on 19 May 2023**